Zusammenfassung
Prävention und Therapie von Knochenmetastasen werden immer bedeutsamer in der interdisziplinären Versorgung von Patientinnen und Patienten mit malignen Erkrankungen. Bei manifesten Knochenmetastasen ist die Therapie mit hochdosierten Antiresorptiva, Bisphosphonaten und Denosumab als Standard etabliert. Mit dieser Behandlung wird eine Verbesserung der Lebensqualität, eine Verzögerung und Reduktion von Metastasierung und skelettalen Komplikationen, bei manchen Tumor-Entitäten auch ein verbessertes Überleben, erreicht. Die Antitumorwirkung der verwendeten Substanzen ist teilweise in vitro gezeigt; inwiefern sie klinische Relevanz besitzt, müssen entsprechende Studien zeigen. In diesem Kapitel wird die Wirkungsweise antiresorptiver Medikamente beschrieben und ihre Wirkung auf Knochenzellen und den Knochenstoffwechsel erläutert. Ein möglicher Einfluss auf Tumorzellen wird pathophysiologisch dargestellt und diskutiert.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
AzimH, Azim HA Jr (2013) Targeting RANKL in breast cancer: bone metastasis and beyond. Expert Rev Anticancer Ther 13: 195–201
Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927–2938
Brown-Glaberman U, Stopeck AT (2012) Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 6: 89–99
Carter JA, Ji X, Botteman MF (2013) Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Rev Pharmacoecon Outcomes Res 13(4): 483–496
Casimiro S, Mohammad KS, Pires R et al (2013) RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PloS one 8: e63153
Clezardin P (2011) Bisphosphonates’ antitumor activity: an unravelled side of a multifaceted drug class. Bone 48: 71–79
Clezardin P (2012) Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anticancer Agents Med Chem 12: 102–113
Clezardin P, Massaia M (2010) Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16: 3007–2014
Clezardin P, Benzaid I, Croucher PI (2011) Bisphosphonates in preclinical bone oncology. Bone 49: 66–70
Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann NY Acad Sci 1218: 3–14
Coleman RE, McCloskey EV (2011) Bisphosphonates in oncology. Bone 49: 71–76
Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104: 1059–1067
Colon-Emeric CS, Mesenbrink P, Lyles KW et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Mineral Res 25: 91–97
Cremers S, Papapoulos S (2011) Pharmacology of bisphosphonates. Bone 49: 42–49
Ebert R, Zeck S, Meissner-Weigl J et al (2012) Kruppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. Bone 50: 723–732
Ebetino FH, Hogan AM, Sun S et al (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49: 20–33
Fields SZ, Parshad S, Anne M et al (2013) Activin receptor antagonists for cancer-related anemia and bone disease. Exp Opin Invest Drugs 22: 87–101
Gertz BJ, Holland SD, Kline WF et al (1993) Clinical pharmacology of alendronate sodium. Osteoporosis Int 3(Suppl 3): S13–16
Gnant M (2012) Adjuvant bisphosphonates: a new standard of care? Curr Opin Oncol 24: 635–642
Gnant M, Dubsky P, Hadji P (2012) Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 192: 65–91
Goessl C, Katz L, Dougall WC et al (2012) The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann NY Acad Sci 1263: 29–40
Gonzalez-Suarez E, Jacob AP, Jones J et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468: 103–107
Hadji P, Aapro M, Costa L, Gnant M (2012a) Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. Cancer Treatment Rev 38: 815–824
Hadji P, Coleman R, Gnant M, Green J (2012b) The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol 23: 2782–2790
Hageman K, Patel KC, Mace K, Cooper MR (2013) The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 47: 1069–1074
Jakob F, Seefried L, Ebert R (2012) Pathophysiologie des Knochenstoffwechsels bei Osteonekrosen im Zusammenhang mit starker antiresorptiver Therapie. Osteologe 21: 186–192
Khosla S, Bilezikian JP, Dempster DW et al (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metabol 97: 2272–2282
Kumagai Y, Hasunuma T, Padhi D (2011) A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone 49: 1101–1107
Lacey DL, Boyle WJ, Simonet WS et al (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discovery 11: 401–419
Langdahl B, Binkley N, Bone H et al (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Mineral Res 27: 2251–2258
Lawson MA, Xia Z, Barnett BL et al (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mat Res Part B, Applied Biomaterials 92: 149–155
Longo V, Brunetti O, D’Oronzo S et al (2012) Therapeutic approaches to myeloma bone disease: an evolving story. Cancer Treat Rev 38: 787–797
Martin PL, Bugelski PJ (2012) Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol 166: 806–822
Mhaskar R, Redzepovic J, Wheatley K et al (2012) Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 5: CD003188
Owen S, Ye L, Sanders AJ et al (2013) Expression profile of receptor activator of nuclear-kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res 33: 199–206
Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39: 97–104
Qi WX, Lin F, He AN et al (2013) Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29: 1067–1073
Rachner TD, Singh SK, Schoppet M et al (2010) Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287: 109–116
Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377: 1276–1287
Rachner TD, Hadji P, Hofbauer LC (2012) Novel therapies in benign and malignant bone diseases. Pharmacol Ther 134: 338–344
Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Translat Med 9: 177
Rogers MJ, Crockett JC, Coxon FP, Monkkonen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49: 34–41
Roodman GD (2012) Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev 31: 569–578
Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49: 2–19
Santini D, Perrone G, Roato I et al (2011a) Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cellular Physiol 226: 780–784
Santini D, Schiavon G, Vincenzi B et al (2011b) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PloS one 6: e19234
Schramek D, Leibbrandt A, Sigl V et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98–102
Sharma A, Chatterjee S, Arbab-Zadeh A et al (2013) Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Chest 144(4): 1311–1322
Sottnik JL, Keller ET (2013) Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med 13: 626–639
Valachis A, Polyzos NP, Coleman RE et al (2013) Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 18: 353–361
Wang H, Sarikonda G, Puan KJ et al (2011) Indirect stimulation of human Vgamma2Vdelta2 T cells through alterations in isoprenoid metabolism. J Immunol 187: 5099–5113
Yan T, Yin W, Zhou Q et al (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48: 187–195
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Jakob, F., Ebert, R. (2014). Antiresorptiva in der Behandlung von Knochenmetastasen. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-662-43471-0_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43470-3
Online ISBN: 978-3-662-43471-0
eBook Packages: Medicine (German Language)